Clinical Trial Search

Primary: NK Cell Activation — 19; 20; 4; 3 percentage of activity

Primary: Median Change in Upper Extremity Fugl Meyer Assessment Score — 4.5; 6.0; 4; 6 scores on a scale — p=0.256

Primary: Feasibility as Assessed by Proportion of Patients Eligible for Intermittent Therapy Who Actually Receive it — 20 Participants

Primary: Median Progression-free Survival — 5 months

Primary: Clinician Assessed Duration of the Classical Herpetic Lesion — 162.7; 163.6 hours

Primary: Quit Status — 0.5; 0.2; 0.7; 0.5 number of days quit

Primary: Progression Free Survival (PFS) — 6.6; 7.5; 7.6 months

Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 0; 0; 0; 0 Participants

Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 0 Participants

Primary: Proportion of Participants Who Are Able to Pair & Apply a Patch Independently & Successfully by the End of the Week 8 Study Visit as Defined by a Score of 91 to 100 on…

Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 2; 0 Participants

Primary: Percentage of Participants With SLE Responder Index (SRI) Response at Week 52 — 43.6; 52.8 Percentage of participants

Primary: Reponse Rate of the Combination Sorafenib and Temsirolimus in I-131 Refractory Thyroid Cancer. — 8; 21; 1 Participants

Primary: Change in Mean Number of Nocturnal Voids From Baseline — -1.63; -1.29 Voids — p=0.112

Primary: Change From End of Pre-treatment Period (Week 0) in Log-transformed Urine Albumin/Creatinine Ratio (UACR) at the End of Treatment Period (Week 12) — 0.152; -0.173…